BREAKING
Arcadia Biosciences 2025 Financial Results 3 minutes ago Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Earnings 7 minutes ago X Financial (XYF) Q4 2025 Earnings Recap 13 minutes ago SBC Medical Group Holdings Incorporated (SBC) Beats Q4 EPS Estimates by 16.7% 29 minutes ago Vivani Medical 2025 Financial Results Analysis 32 minutes ago Huize Holding Limited (HUIZ) Reports Q4 Earnings 33 minutes ago Oxford Industries Fiscal 2025 Financial Review 46 minutes ago Southland Holdings, Inc. (SLND) Reports Wider Q4 Loss Than Expected 46 minutes ago CapsoVision 2025 Financial Performance Review 1 hour ago Financial Overview: Nortech Systems 2025 Performance 1 hour ago Arcadia Biosciences 2025 Financial Results 3 minutes ago Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Earnings 7 minutes ago X Financial (XYF) Q4 2025 Earnings Recap 13 minutes ago SBC Medical Group Holdings Incorporated (SBC) Beats Q4 EPS Estimates by 16.7% 29 minutes ago Vivani Medical 2025 Financial Results Analysis 32 minutes ago Huize Holding Limited (HUIZ) Reports Q4 Earnings 33 minutes ago Oxford Industries Fiscal 2025 Financial Review 46 minutes ago Southland Holdings, Inc. (SLND) Reports Wider Q4 Loss Than Expected 46 minutes ago CapsoVision 2025 Financial Performance Review 1 hour ago Financial Overview: Nortech Systems 2025 Performance 1 hour ago
ADVERTISEMENT
Breaking News

Arcadia Biosciences 2025 Financial Results

Arcadia Biosciences, Inc.

March 27, 2026 1 min read

Arcadia Biosciences, Inc.

RKDARKDA|EPS -$0.97|Rev $901,000|Net Loss $1.4M

Arcadia Biosciences produces innovative wellness products. Recently, the company terminated a proposed business combination with Roosevelt Resources. Arcadia is now focused on growing its Zola® coconut water brand while evaluating strategic alternatives.

For the full year 2025, total revenues were $4,858,000. The net loss (EPS) was $1.71 per share for the year. Fourth-quarter revenues were $901,000 , with an EPS loss of $0.97 per share.

Zola brand revenues increased 17% year-over-year. Furthermore, Arcadia secured approximately $2.1 million in gross proceeds from the exercise of preferred investment options to improve its balance sheet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT